KERANOVA wins the Start-up Trophy of Region Auvergne Rhône Alpes 2018 in the Medtech category, as well as the "Favorite of the Public" Award, all categories combined. A magnificent success that distinguishes KERANOVA, its technological breakthrough and its global ambition to revolutionize cataract surgery with the first intelligent, ultra-fast robotic system.
Keranova presented at the recent Ophthalmology Innovation Summit conference in Washington on April 12 in front of a crowded room, a video explaining the principle of its new ultra-fast laser and its use as part of a cataract surgery performing a photoemulsification® . A huge buzz came with this screening, which shed light on this [...]
KERANOVA has been confirmed by the selection committee to present at the next OIS conference in washington, April, 12th. For this opportunity and for the first time KERANOVA will present publicly its innovation and the first pre-clinical results. OIS 2018 agenda
Saint Etienne, February 2018 - The BPI team and the General Commissariat for Investment (French Government), after 7 months of study of the KERANOVA project, decided to give a very significant help to our company, convinced of the important potential and the need to support a possible future leader of ophthalmology in France with a [...]
KERANOVA opens its administrative site at Vénissieux and begins construction on its headquarters in Saint Etienne
Work on KERANOVA’s headquarters is under way in a former manufacturing site. The new building will house technical teams, R&D and production and will feature a controlled atmosphere zone. Work is expected to be completed in early May 2016, at which point activities in the 500 m2 site will begin right away. KERANOVA’s administrative, marketing, [...]
KERANOVA announces the success of its first round of financing for 4 million euros, with an additional 1 million euro of support from Bpifrance. The potential of KERANOVA’s project was able to attract renowned investors active in life sciences. This funding envelope will enable the company to reach the clinical study phase required before new [...]